Niacinamide–Ceramide Conjugate: In Vitro Bioactivities and 28-Day Clinical Evidence for Multitarget Skincare
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Niacinamide (NAM) and ceramides are well-established skincare ingredients with distinct yet complementary biological mechanisms. Nevertheless, simple physical blending of these two actives presents practical limitations for topical application. To address this, the present study evaluated SuperCera N-Nicotinamide(P) (NAM-Cer), a niacinamide–ceramide covalent conjugate conceived to integrate bioactivities derived from each parent moiety within a single molecular framework. Employing an integrated workflow combining in vitro cellular assays and a 28-day randomized clinical trial, we identified multiple cellular-level bioactivities of NAM-Cer, including elastase inhibition, upregulation of type I collagen (COL1A1) and aquaporin-3 (AQP3), suppression of melanogenesis and tyrosinase activity, and downregulation of matrix metalloproteinase-1 (MMP-1). Clinical evaluation revealed significant, concentration-dependent improvements in skin hydration, elasticity, firmness, brightness, and antiwrinkle efficacy, along with favorable cutaneous tolerability. In summary, NAM-Cer is a safe, multitarget skincare candidate that elicits diverse skin-beneficial bioactivities in vitro and drives concentration-dependent cutaneous improvements in short-term human topical use.
Source: ACS Omega
Institution: Guangdong Pharmaceutical University
Language: English
Topic: Skin Protection and Aging
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,935
Awards: G9001387464, G9001389677, G9001392479
OpenAlex ID: W7234616341
